List of Vendor Companies in United Kingdom - 229

4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.

At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

Absolute Antibody Ltd is a UK-based biotechnology company founded in Oxford in August 2012. It specializes in recombinant antibody technology and operates from an ISO 9001:2015 certified facility in Redcar, England. The company focuses on improving antibody reproducibility through genetically defined production methods. The core services include recombinant antibody production using mammalian HEK and CHO cell lines, allowing for animal-free and serum-free manufacturing. They also offer custom engineering, providing antibody sequencing and reformatting into over 180 formats, as well as bespoke projects for pharmaceutical, diagnostic, and academic clients. Their product range features over 21,000 defined recombinant antibodies, ensuring consistency across batches, and includes specialized formats for various applications. Absolute Antibody serves a diverse clientele, including 14 of the top 15 pharmaceutical companies by R&D expenditure, biotechnology firms, and academic institutions. The company emphasizes collaboration in therapeutic antibody development and assay standardization.

Activatec develops technologies to produce biobased ingredients from renewable sources. We are specialised in the evaluation, scale-up and commercialisation of processes to produce biotechnological and plant-based ingredients and materials from currently unused and low-value organic sources. Activatec is a B2B Partner that provides support to the industrial biotechnology sector in the form of research services on a contract basis. We are currently working within a number of international partner projects to design, develop and scale-up novel technologies for the production of emerging and high-value bio-based products.

Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients' lives by providing the specialty, hospital, and rare disease medicines they depend on. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients. Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia. Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations. ADVANZ PHARMA's product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products and pipeline cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases. We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.

Who are we? We are AF ChemPharm, established in Sheffield, England, in 1998. We are a chemistry-based contract research organisation, and are specialists in driving discovery by simplifying synthesis. We provide a straightforward, cost-effective and convenient route for bringing expertise in chemical synthesis into your projects. Whatever your core focus, AF ChemPharm is on hand to help you streamline your workflow if you require chemical synthesis. Though we are principally involved in the drug discovery and pharmaceutical sectors, we are a reactive and versatile company, and have current and previous clients from a diverse range of industries. We've worked with biomedical academic research groups, functionalised polymer manufacturers, fine chemical suppliers and emerging-technology firms, amongst many others. What do we offer? Our clients expect high quality, reliable and cost-effective consultancy, custom synthesis and contract research, and we are proud to say that we can deliver on these expectations. We are situated in purpose-designed, state-of-the-art laboratories in central Sheffield, equipped with kilo-lab facilities, and we use a world-class analytical suite for the characterisation of your projects. We work with multi-national companies, universities, SME's and brand new start-ups; whatever the size and direction of your company, we pledge the same commitment to excellence in science, communication and customer service . Our team are all PhD chemists, with backgrounds in synthetic organic and organometallic chemistry from both academia and industry, and we have recently appointed two external scientific advisors of the highest calibre - Prof. Joe Harrity of Sheffield University and Prof. Alan Spivey of Imperial College, London.

AgeCurve Limited is a company that offers tools to measure scalable single cell somatic mutation burden across the life sciences market space. They also provide a deep age profiling kit intended to calculate comprehensive biological aging patterns in a saliva sample.

Alacrita is a pharma and biotech consulting firm whose value to clients is founded on the first-hand experience of its subject-matter experts. Consultants who have spent their careers discovering, developing, manufacturing and commercializing drug products. Our core team leverages a purpose-built network of over 250 such experts who are brought into project teams when specialist expertise is needed. This allows us to provide clients with precisely relevant support on a range of R&D and business issues. We do this while also offering the speed and flexibility expected from a professional life science consulting firm. Our expert teams are ready to support you through every step of the pharmaceutical product development process, leveraging our scientific, clinical and commercial expertise to help you maximize value at each stage. We offer substantial expertise & experience in the following areas: Product Development Services: - Clinical Development - CMC & Supply Chain - Interim Chief Medical Officer Support - Preclinical Strategy & Execution - Regulatory Affairs - Research & IP Evaluation Strategy & Commercialization Services: - Business Plans & Fundraising Support - Opportunity Mapping - New Product Planning - Launch Planning Business Development Services: - Asset Scouting - Due Diligence - Licensing, Partnering & Dealmaking - Pharma & Biotech Valuations Visit www.alacrita.com to learn more.

Alesi Surgical announced in 2023 that it had attained FDA clearance for its groundbreaking Ultravision2 smoke management solution. The breakthrough new Ultravision system includes the world's first surgical tool integrating electrosurgery and class-leading surgical smoke control in a single laparoscopic device. Alesi Surgical was founded to develop and commercialise products that improve the safety, efficacy, and outcomes of surgical procedures. The company is a spin-out of the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experienced surgeons, surgical trainers, and trainees, which allows it to identify issues in procedures and design devices to address these issues. The company is active in the research and development of novel surgical technologies. It has a ‘needs-driven' pipeline and product development is informed by robust testing by surgical trainers who advise on the utility, usability, and integration of products into surgical practice. Ultravision is designed to deliver rapid and continuous resolution of surgical smoke. It is a small, stand-alone, portable unit fully compatible with current laparoscopic equipment and electrosurgical instruments. Alesi Surgical welcomes approaches from research-based companies or inventors who are interested in exploring potential synergies.

Welcome to Anatomise Biostats. Our biostatistics services are designed to support Biopharma and Medtech/Medical Device SMEs and start-ups in their R&D and clinical trials projects throughout the regulatory approval process and beyond. 💡 Our Mission: We aim to facilitate innovation in the life sciences sector while assuring patient benefit and safety, offering unwavering support throughout your journey. 🌐 Who We Serve: Our services cater exclusively to Biopharma and Medtech/Medical Device SMEs and start-ups, and are fine-tuned to address unique industry challenges as they arise. 📈 Specialized Expertise: Our team of biostatistics and bioinformatics experts ensures data-driven precision in your R&D and clinical trials. 🔍 Navigating Regulatory Waters: We guide you through evolving regulatory requirements with confidence. 🤝 Dedicated Partnership: We're not just consultants; we're committed to the success of your project and longer-term pipeline. 🌟 Results-Focused: Our focus is on delivering accurate insights for informed decision-making. Ready to embark on your life sciences journey? Connect with Anatomise Biostats today, and let's chart a course to success together. #Biostatistics #Bioinformatics #LifeSciences #Medtech #Biopharma #BiometricsConsulting #RegulatoryApproval #ClinicalTrials #FunctionalServiceProvider

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE’s GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for the pharmaceutical industry. Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Anuva is creating the world's most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

APS Biocontrol Ltd. (APS) develops biocontrol solutions for the management of bacterial diseases and other microbial contaminants in agriculture and food processing, where concerns regarding the use of synthetic chemicals have resulted in a programme of withdrawals that will have a dramatic impact on the ability of (a) growers to achieve commercial yields and quality and (b) suppliers to ensure the quality of post-harvest packed produce. APS' patented Biolyse technology (based on naturally-occurring antimicrobials; bacteriophage) provides safe, effective and environmentally-sustainable replacements. If you have a problem with bacterial breakdown or contamination, in any sector, our Biolyse technology could be an effective solution. APS is also the company behind Scotland's favourite insect repellent, Smidge (further details can be found at www.smidgeup.com)

Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Get our newsletter: https://aptamergroup.com/newsletter

Arctoris Ltd is a biotechnology company founded in 2016 and based in Oxford, UK, with additional locations in Singapore, Boston, and Abu Dhabi. It operates as a tech-enabled Partnership Research Organization (PRO) and utilizes its proprietary Ulysses platform, the first fully automated drug discovery platform, to enhance research and development processes for biotech, pharmaceutical, and academic partners. The company employs over 40 experts in various fields, including cellular and molecular biology, biochemistry, and machine learning. Arctoris offers services such as Experiments-as-a-Service, integrated drug discovery, and collaborative R&D, providing end-to-end support from target identification to preclinical candidate development. The Ulysses platform combines robotics and advanced data science to deliver high-quality datasets, reducing human error and accelerating project timelines. Arctoris collaborates with biotech startups, large pharmaceutical companies, and AI-driven drug discovery firms, focusing on oncology, neurology, and other therapeutic areas.

Arrayjet Ltd is accredited to ISO13485 and providesCRO/CMO liquid handling solutions to support a variety of microarray applications. Their high-speed microarray spotters utilize a patented, non-contact, inkjet technologyfor printing multiplex array-based assays onto slides, Point-Of-Care devices, biochips and microplates.COVID-19: Re-purposed its in-house antibody screening technology to create a population-scale diagnostic program that will help scientists better understand the behavior of the COVID-19 virus and further the rapidity of a global vaccination program.

Ascend is a development partner that supports life-science innovators in bringing gene therapy products to patients. Our team has deep expertise in gene therapy development and commercialization to offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together!

Astoriom is a globally recognised leader in outsourced stability storage and biorepository solutions, with over 30 years of industry experience. We specialise in providing comprehensive stability storage and validation services to pharmaceutical companies, biotech firms, medical device manufacturers, and other life science organisations worldwide. Our services ensure the highest standards of quality and compliance, making us a trusted partner in the industry. Why Astoriom: - Expert Team: Our highly experienced and trusted professionals ensure the highest quality of service. With decades of expertise, our team is dedicated to maintaining the integrity of your products. - Extensive Capacity: We offer over half a million cubic feet of storage at all ICH conditions, accommodating a wide range of temperatures from liquid nitrogen-cooled -196C to +60C. This vast capacity allows us to meet diverse client needs efficiently. - State-of-the-Art Systems: Our automated inventory system and 24/7 alarming ensure robust security, and continuous monitoring. Our systems are designed to provide real-time updates and immediate alerts to ensure the safety and stability of your products. - On-Site Engineers: Dedicated service and validation engineers are available on-site, providing immediate support and maintenance ensuring the continuous operation of storage systems. Astoriom's Core Services: - Stability Storage - Biorepository - Accelerated Ageing Testing - Disaster Recovery - Photostability - Thermal Cycling - Validation Service - 24/7/365 On-Call Repair At Astoriom, every sample matters because everyone's health matters. We are committed to treating each sample entrusted to us with the utmost care, providing reliable and innovative solutions worldwide to ensure the integrity and safety of your products.

Crafting shelf-stable science inspired by hedgehogs, Atelerix is the answer to the cryopreservation headache. With a gel that's not just cool but doesn't need to be cold, they're setting cells, tissues, and viruses free from the icy grip of traditional storage and shipping methods. Welcome to the future of bioscience, where the storage is easy, and the cells are always fresh.

PROVIDING DMPK & CLINICAL PHARMACOLOGY EXPERTISE TO PHARMA, BIOTECH, ACADEMIC & CHARITABLE ORGANISATIONS. Aucuba Sciences Ltd was established in 2016. Specialising in DMPK and Clinical Pharmacology knowledge for drug discovery and development programmes, the company provides advice and expertise to assist in the resolution of drug discovery and development challenges.

Aurora specializes in minimally invasive, regenerative technologies. It is our vision to be the leader in advanced spinal technologies which will impact lives worldwide. Based in Carlsbad, California we design, develop and manufacture quality spinal implants to be sold worldwide.

Autoscribe offers a wide portfolio of Laboratory Information Management Systems (LIMS). We develop, implement and support configurable Solutions for customers in the USA, UK and worldwide in a variety of industries, such as: - Pharmaceuticals; Drug Discovery, Development & Manufacture - Healthcare & Medical Research - Biobanking - Veterinary - Petrochemicals - Food & Beverage - Energy & Power Utilities - Minerals & Mining - Building & Construction - Environmental Management - Telecommunications - Consumer Products - Contract Testing Laboratories Available on and off the shelf, our scalable, fully configurable LIMS, help our customers manage their laboratory workflow in a key areas such as, but not limited to: - Individual & Bulk sample Entry / Registration - Sample Reception, Preparation, & Allocation - Creation of Test suites - Test Scheduling - Result entry & Validation - Quality Control - Result Approval & Report Analysis Further benefits which add value to our solutions are: - Dynamic Reporting - Barcoding Capability - Competency Monitoring and Management - Resource Planning - Instrument Calibration and Maintenance - Instrument Data Importing - Complaints & Feedback Management - Regulatory Compliance for Audit - In-built Future Proofing - Concurrent, Perpetual Licences - Ability to link to multiple on or off-site Labs - Proof of Concept available - Localized Support for all International customers Autoscribe also regularly hosts free Seminars and Training Workshops. For more details, visit our official website below:

Axis Shield is a company that specializes in the development and manufacture of in vitro diagnostic tests, focusing on proprietary markers for early diagnosis and management of critical illnesses like cardiovascular and neurodegenerative diseases.

World leaders in iPSC technology supporting the next generation of advanced models for drug discovery We provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, we support the pursuit of more human-relevant in vitro models to develop better, safer therapies. We have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Our industry-leading iPSC capabilities support the pursuit of advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms. From simple monoculture models to complex co- and tri-culture and 3D models, we continue to pioneer the advanced utility of iPSCs for research and drug discovery.

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. Our exclusive access to nature's greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

Badrilla is a biological reagents company focused on providing effective, well validated research antibodies to cardiac proteins, chemistry kits for the study of S-palmitoylation and standards for precise and accurate quantification of immunoassay data. Do you need reagents for your research project that are not currently available? We work with researchers to develop new probes in emerging areas of research, bringing them to the whole community after prompt and thorough characterisation. Approach us with your ideas, we'd like to work together.

Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global genetic biodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most.

BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence

BioCorteX is a biotechnology company that utilizes artificial intelligence and computational modeling to enhance therapeutic development, particularly in the area of microbiome-host interactions. The company operates through two entities: Biocortex Ltd, established in the UK in 2021, and BIOCORTEX, INC., which opened in 2023. BioCorteX specializes in AI-driven platforms that aim to reduce risks in drug development and improve clinical trial outcomes. The company offers several core services, including in silico clinical trials that simulate drug-bacteria-host interactions to predict clinical outcomes, microbiome analysis to assess how bacterial diversity affects drug efficacy, and therapeutic development support for various sectors such as pharmaceuticals and cosmetics. Their proprietary foundational emulator integrates microbiome data with AI to simulate human physiological responses to drugs, while their drug interaction models test numerous medications to identify success factors, particularly in antibody-drug conjugates for cancer therapy. BioCorteX targets pharmaceutical companies, biotech firms, and the cosmetics industry, providing insights to optimize product performance and safety.

At Biofortuna we form unique partnerships with the most innovative healthcare and life science companies and work together to enhance health and wellbeing all over the world. Our services are wide-ranging, and whether we are supporting diagnostic companies, food safety experts or life science specialists our objectives are the same; to form long term partnerships and become a valued extension of your team. We do that by solving problems and presenting opportunities. We listen to your requirements, develop customised solutions and deliver them with openness and transparency. Operating from state-of-the art, purpose built premises, and benefiting from ISO 13485 certification, ISO 17025 accreditation and FDA registration, we have a proven track record in the development and large-scale manufacture of PCR and LAMP molecular assays and immunoassays.

We have 24 years of experience doing Process Simulation and Economic Analysis! Our software has 15 years of history now. You may know BioSolve Process, which can let you evaluate the following and beyond: - Process Optimization - Process Simulation - Techno-Economic Assessment - Green Design which can feed into LCA Our users can be: - MSAT - R&D Scientists - Managements to review the data - Tech Transfer - Innovative Supplier - Engineers Back in December 1998, Biopharm Services was founded by Andrew Sinclair to develop technology solutions and services for: - the biopharmaceutical manufacturing business - covering biologic products (inc. viral vectors, mRNA, ADC and more) - and facilities and manufacturing strategy

Briefly helps give scientists headspace to design their experiments.  Our experiment builder helps create clear, consistent, visual experimental plans, with a copilot that takes care of the busywork.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

C3 Biotech emerged out of the Manchester Institute of Biotechnology in 2015 by founders Professor Nigel Scrutton FRS and Michael Smith. They were driven by a vision to create a better world by providing sustainable and innovative solutions to meet the impending energy crisis. This vision is rooted in foundational science that has emerged from the engineering of biology, but is shaped by the need to urgently establish industrial manufacturing at scale. This idea is at the heart of C3. Building a better world doesn't mean reimagining what we do but the way we do it – sustainable fuels that clean up the planet and save natural resources is the first step in achieving global net zero goals, whilst tackling the impending energy crisis. C3 is now positioned to grow its pioneering technology to be catalysts of industrialisation in biomanufacturing.

Cambridge Nucleomics is a biotechnology company that specializes in fast and easy RNA measurement at scale with single-molecule accuracy.

Cambridge Protein Arrays Ltd. is a SME founded in 2010 and located in Cambridge, United Kingdom. We offer products and customised services in the area of protein microarrays and related areas. We are the distributors of HuProt™ arrays, the largest human protein arrays available, with more than 23,000 human proteins, representing 80% of the human protein coding genome, on a single slide. HuProt™ arrays have been successfully used for antibody and small molecule specificity screening, autoimmune antibody profiling, and interactomics. Cambridge Protein Arrays Ltd. also offers customised protein array services for high throughput screening, autoimmune biomarker validation, and tailored consulting services in the microarrays and antibody area.

Cambridge Research Biochemicals is a biotechnology company that specializes in custom-made peptide and antibody tools.

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3D™ bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies. Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

Celentyx Ltd is a ‘boutique’ CRO providing bespoke drug discovery services focused on human immunology across a broad range of therapeutic areas including autoimmunity, COVID-19, inflammation, immuno-oncology, fibrosis and neuroinflammation. Celentyx has a highly experienced scientific team that develops and provides assays using human primary cells at all stages of the drug discovery pipeline. Situated in close proximity to major hospitals and blood services (with established partnerships), assays can be performed at scale using blood and tissue from healthy volunteers and patients with defined disease including deep access to their clinical records. Celentyx has well-established assay platforms in multi-colour flow-cytometry, Cytof, high-content imaging, multiplex supernatant analysis (Luminex), super-resolution microscopy as well as proteomic and molecular biology capability, enabling high-resolution analysis of the human immune system for target discovery, screening, candidate selection, mechanism of action, and biomarker studies. Celentyx is based in the UK (Oxford and Birmingham) and in addition to internationally recognised scientists within the company, benefits from the world-leading expertise of neighbouring translational medicine departments at the Universities of Oxford and Birmingham.

The Offshore Renewable Energy (ORE) Catapult forms part of an elite network of eight technology and innovation centres established and overseen by Innovate UK, which represents a £1bn public and private sector investment over the next five years. ORE Catapult is the UK's flagship technology innovation and research centre for offshore wind, wave and tidal energy. We deliver prioritised research underpinned by world-class test and demonstration facilities, collaborating with industry, academia and Government to reduce the cost of offshore renewable energy and create UK economic benefit.

Cellesce Ltd is a biotechnology company based in Cardiff, Wales, that focuses on organoid research and bioprocessing technologies. Established in 2013, the company specializes in patient-derived organoids (PDOs) for cancer research, utilizing patented bioprocessing technology to standardize and scale organoid production. The company offers several core services, including the development and manufacturing of standardized cancer organoids for large-scale applications such as compound screening and high-throughput drug discovery. Cellesce also provides scale-up solutions to ensure reproducible organoid batches, meeting the needs of pharmaceutical testing. Additionally, it supports drug discovery pipelines with customized organoid models, particularly in oncology. In December 2022, Cellesce was acquired by Molecular Devices, enhancing its capabilities in integrating organoid technology into drug discovery platforms. The company reported $7.8 million in annual revenue for 2024 and operates with a small team, emphasizing its commitment to advancing organoid-based precision medicine.

Manchester Biogel PeptiGel products are now part of Cell Guidance Systems. PeptiGel technology allows us to offer a family of high-quality peptide hydrogels, with a range of mechanical and functional properties, to enable you to find the most suitable materials for your application needs. PeptiGel hydrogels mimic the cell micro-environment and provide a natural physiological extracellular matrix that open up exciting new opportunities within the fields of 3D cell-culture, 3D bioprinting, regenerative medicine and medical devices to solve current healthcare challenges. Our technical support is available to help you realise your research ambition.

We are a UK-based company specialising in manufacturing and worldwide supply of consumables, equipment, and services to the cellular pathology sector. The CellPath name is synonymous with innovative, precise and well-proven products manufactured to a very high standard. We have a state-of-the-art injection moulding capability at our headquarters in Wales, allowing us to differentiate ourselves in the marketplace by directly manufacturing many of the plastic products used in modern histology and cytology laboratories. Expansion and infrastructure investment over recent years have increased our manufacturing capability, allowing us to introduce additional products to the market such as chemicals, stains, tissue marking dyes and fixatives. CellPath has a continuous improvement process built around a strong desire to maintain a high level of quality, and we are currently certified to ISO 13485:2016 standards.

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

Pharmaceutical Services

By mining the genome using our bioinformatics platform we discover and re-purpose natural gene regulatory elements, creating customised gene expression systems to: 1. Improve human health: Creating highly selective and controllable promoters and gene expression cassettes for novel gene and cell therapy systems. Improving the efficiency of biologics production by increasing protein yields in upstream manufacturing processes. 2. Engineer biology: Harnessing synthetic biology to make promoters for a wide array of chassis organisms used in Industrial Biotech. Creating switches and gene circuits that can be employed in the metabolic engineering applications. 3. Enable traits discovery: Designing tissue-selective plant synthetic promoters active across different crop species for Agricultural Biotech applications. Using plant genomics to facilitate the design of environmentally-regulated and pathogen-responsive promoters.

Chromocyte is a FREE impartial and innovative online resource for designing complex multi-parameter flow cytometry antibody panels and finding the reagents and antibodies that are required for these and other related techniques. Chromocyte includes intuitive interfaces which highlight the latest flow cytometry products and services and will be an invaluable sales and marketing vehicle for those supplying flow cytometry related products and antibodies. Users can input the configuration of their own flow cytometry instruments and search for antibodies in the context of these. We also have a Core Facility Administration Area which allows flow cytometry configurations to be shared by Users in the same facility. We also offer a unique interface for generating antibody search panels - a great time saver! Chromocyte is somewhat unique in that is is based on the solid and developing academic background in flow cytometry of its Founder. We can therefore provide invaluable insights into current developments and the specific needs of the academic and research communities.

Cirdan designs, manufactures and supplies innovative software and imaging solutions for the acceleration and enhancement of diagnosis. Our systems are optimised for pathology and clinical laboratory usage. Cirdan's primary product is its world-class Laboratory Information System, ULTRA. ULTRA has been designed to streamline laboratory operations and is currently installed in more than 72 laboratories across 6 continents. Another core product is PathLite Compact, a purpose-built system designed specifically for gross imaging within clinical laboratories. The company was founded in 2010 and is headquartered in Lisburn, Northern Ireland and has additional offices in Canada and Australia. Cirdan is also responsible for organising Pathology Horizons, an annual and open CPD conference on the future of pathology. For more information visit - www.pathologyhorizons.com

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

A leader in next-generation prebiotic galactooligosaccharides (GOS), Clasado Biosciences is your partner of choice for scientifically supported prebiotic product development. Established in Reading, United Kingdom in 2004 and celebrating almost two decades of scientifically backed prebiotic expertise, Clasado is the team behind multi award-winning ingredient, Bimuno® GOS, a prebiotic trusted by health and nutrition brands worldwide. The ingredient's capabilities for improving health and well-being are supported by more than 120 publications, giving it the most comprehensive research portfolio of any commercially available GOS. These publications demonstrate how it can support health in areas such as gastrointestinal, immune and cognitive health across various applications from supplements and medical nutrition to functional food and beverages. Highly stable, with a low efficacious daily dose, and health claims available in specific geographies, Bimuno GOS offers premier levels of added value to formulations. Clasado is also the developer behind a range of finished D2C prebiotic supplements, including Bimuno Original (rebranded from Bimuno Daily) which support better everyday health, from the gut.

Cambridge Medical Robotics was created to bring the benefits of minimal access surgery to millions more patients each year. The company'saim is to make minimal access surgery available to all by delivering a robotic tool that empowers surgeons and delivers value-driven outcomes for healthcare providers.

Cobra Biologics, a Charles River company, is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The team at Cobra's GMP approved facilities has expertise tailored to serving customers around the world; offering a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs in only months.

Colorifix usessynthetic biology to engineer microbes toconvert agricultural by-products into dyes.The dyeing industry is one of the largest water consumers in the world, using over 5 trillion litres per year along with petrochemical dyes and a host of toxic and highly polluting chemicals. According to the World Bank, textile dyeing accounts for around 20% of global industrial water pollution. Textile dyeing pollution uses up to 1.2 kilos of chemicals per kilo of fabric, only 50 grams of it being dye. Approximately 70 highly toxic chemicals are routinely used in textile processing, and up to 30 of them are irretrievable.

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.

Consone AI a disruptive technology platform targeting how decisions are made in the drug development process. Accelerating new medicines to market, reducing cost, reducing preclinical toxic trials, time and environmental footprints. The Consone AI platform will empower user decision making by successfully predicting toxicological effects and viability of new drugs.

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

Founded in 1946 in Nottingham, UK, Copley Scientific remains family owned and managed. We are recognised as the world's leading manufacturer of inhaler test equipment, in addition to being a trusted provider of test instrumentation for other pharmaceutical dosage forms including tablets, capsules, transdermals, semisolids, powders, suppositories and detergents. Copley continues to work closely with industry groups and leading experts to bring relevant new products to market, with all equipment backed by expert training and lifetime support. Committed to excellence, Copley aims to deliver exemplary service for an outstanding customer experience. With over 1,200 customers across 96 countries, including 9 of the world's 10 largest pharmaceutical companies, Copley prides itself on the highest quality products and service. It also remains true to its founding principle of meeting customer requirements through continuous innovation, over 75 years on. Visit www.copleyscientific.com for further information.

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

CryoLogyx specializes in developing and producing high-quality, cryopreservation solutions. The cryopreserved cells are designed to cater to the critical needs of the drug discovery, which is powered by the patented formulation - Cryoshield™. Freezing and thawing processes can be particularly stressful for cells, often resulting in reduced viability and recovery due to ice crystal formation and other factors. And the repetitive tasks of cell culture, including numerous counting and handling procedures, take significant time that researchers could otherwise dedicate to more critical aspects of their research. At CryoLogyx, we are building a future where assay-ready cells are the default option in cellbiology, and research outcomes are accelerated by weeks and months using products that enable experimental reproducibility and unparalleled ease of use.

Healthcare needs to be reinvented. Our mission is to shorten patient journeys and medical workflows, powered by an internal EHR ecosystem. Our vision is to change healthcare to make it more accessible, decentralised and efficient through combining strategy, economics and digital. Cw1 believes in equality and it is committed to make a difference. Visit us at www.cw1.com or just see you around.

Cytocell is a biotechnology company that specializes in designing and manufacturing a variety of fluorescence in situ hybridisation (FISH) probes.

Providing predictive analytics from suspended-cells through our unbiased cytometry technology, AuraCyt™

At Aerbio, we’re powering the future of fermentation technology. We utilise hydrogen and carbon dioxide, instead of sugar, to fuel the creation of a range of products. Leading the charge with our groundbreaking single cell protein, Proton™, we are boldly redefining sustainability and innovation in industrial biotechnology.

We are a big-data and analysis company focused on enabling reproducibility and predictability in chemistry. With machine learning (ML) and AI powered products, SmartChemistry® empowers the chemist to design, experiment and understand their chemistry on an unprecedented scale. Utilising an advanced knowledge base that combines reaction data, real time sensor data and outcomes, SmartChemistry® enables access to a higher level of experimentation in the chemistry laboratory.

DefiniGEN are a Cambridge UK company providing highly functionalhuman cell productsincludingliver, pancreas, lung,and intestinal cells pluscustom servicesfor drug discovery and disease model generation.

DiagNodus is a biomedical research services company that specializes in pathology and molecular biology, offering laboratory-based projects, research design, clinical trial services, and sample analysis.

DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide comprehensive, actionable information to clinicians in a matter of hours, versus days. DNAe’s initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring. DNAe has received “Breakthrough Device” designation from the US Food and Drug Administration (FDA) for its pioneering platform and first assay. Headquartered in London, UK, DNAe has expanded operations further in with a clinical diagnostic development and manufacturing site in San Diego, CA. We are always on the lookout for exceptional talent. For more details, visit www.dnae.com. Or get in touch, we would love to hear from you. Twitter: @dna_electronics Instagram: dna.electronics

DNA Worldwide is a specialist DNA, Hair Drug & Alcohol testing company providing a comprehensive range of home and legal DNA tests. DNA Worldwide concentrates on quality and customer service certified to ISO 9001:2008. It exceeds all UK and international requirements for testing through its ISO:17025 certified partner laboratory. All tests are dealt with discretely, efficiently and are subject to the highest levels of security with accuracy of 100%. A team of over 200 leading industry scientists is backed up by dedicated and supportive customer care, regularly dealing with paternity testing for family disputes, immigration testing as well as more complex testing of special specimens. The company also offers siblingship, Aunt/Uncle testing and Grandparent testing.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. Combining a workflow and data platform with best-of-breed applications, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Trusted by more than 2 million researchers from the world's leading biopharma, chemicals and materials enterprises, and academic institutions, we are dedicated to working with the scientific community to help make the world a healthier, cleaner and safer place to live. Learn more about our platform and products, including GraphPad Prism, Geneious, SnapGene, Protein Metrics, LabArchives, and more, at https://dotmatics.com.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

Eden Bio uses machine learning to improve protein yield, saving companies time and money, and helping them get their proteins to market faster.

EKF is a leading global diagnostics and biotechnology company specialising in the development, production, and distribution of leading medical technologies and patient-centric solutions. Our diagnostic technologies and biotechnology solutions empower healthcare professionals and non-medical practitioners to make informed decisions through point-of-care testing and life sciences applications. Point-of-Care: EKF develops and manufactures medical devices and tests (in-vitro diagnostics (IVD)) that can be used at or near the patient's location. Designed to provide quick and accurate results, these tests (and optional data connectivity software) enable healthcare professionals to make rapid decisions. Diabetes care: EKF offers a range of products related to diabetes care, including glucose monitoring systems and associated supplies and consumables. Hematology solutions: EKF provides products, supplies, and consumables for measuring hemoglobin levels, including those used for the detection of hemoglobin variants. Life Sciences: EKF develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and other bio-materials used in the research, biotechnology, and pharmaceutical industries. Dedicated to supporting clinicians, scientists and researchers these high-quality materials can be used in multiple applications. Enzyme Fermentation: EKF offers precision fermentation, custom bioprocessing and contract manufacturing services related to the production of pharmaceuticals and other biologics. Beta-hydroxybutyrate (β-HB): EKF provides β-HB products which are used to detect ketones, to help identify patients suffering from diabetic ketoacidosis, and other clinical applications. As a global leader in the development and distribution of diagnostic technologies and biotechnology solutions, EKF has a presence in over 120 countries with the solutions needed to support better health and wellness worldwide.

Yourgene Health is a leading integrated technologies and services business, enabling the delivery of genomic medicine. Yourgene works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. Flagship in vitro diagnostic products include Non-Invasive Prenatal Tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping. Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the LightBench® and the LightBench® Detect instruments are ideal for cell-free DNA applications in NIPT, gene synthesis and oncology, including liquid biopsy. Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. Yourgene Health is headquartered in Manchester, UK with facilities in Singapore, the US and Canada. Yourgene is now part of the Novacyt group of companies. For more information visit www.yourgenehealth.com

Enigma Diagnostics is a PCR-based testing out of the laboratory with a range of simple-to-use products.

Epistem Ltd. is a leading contract service provider offering innovative preclinical research services, genetic and protein biomarker testing as well as histology services to pharmaceutical, biotech and academic customers to support to drug discovery and development pipelines. We have worked with over 200 pharmaceutical and biotechnology companies at both preclinical and clinical stages. Our high level of expertise and customer focus has led to an enviable track record and impressive amount of repeat business. Our preclinical contract research services group advance drug development programs for oncology, inflammatory, dermatology, auto-immune and GI disease indications. We offer an impressive range of preclinical models in these therapeutic areas. We also provide information relating to toxicity assessments and are experts in GI tox. We also offer a broad range of cell based assays including novel stem cell assays. Our biomarker services division offers GCLP compliant genetic testing, histology, FACS analysis and protein biomarker detection. Epistem’s genetics group offer gene expression and DNA genotyping sample analysis by NGS, microarray and qPCR. We specialise in working with small starting materials (down to a single cell input) applying our proprietary low input techniques and products to support drug development programs. We are specialists in fractionating cell populations and conducting genetic analysis. We have pioneered techniques using plucked scalp hair and laser capture microdissected material to provide gene expression biomarker information to drug development programs. Epistem is committed to provide reliable and innovative services to support all phases of drug development from to preclinical projects to clinical trials. Website: www.epsitem.co.uk

Epoch's biorecycling platform unlocks circularity for the toughest-to-recycle materials. Our AI-designed enzymes enable infinite recycling for mixed plastics and textiles at low temperatures. We produce sustainable outputs for use in apparel, automotive, packaging and more.

Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.

Evonetix is set to revolutionizede novogene synthesis to facilitate the fast-growing and exciting field of synthetic biology.The company's unique selling point is driven by high fidelity and parallelization of gene synthesis.Evonetix's technology is based upon a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of 10,000 miniaturized reaction sites, allowing massive parallelism in the DNA synthesis process and therefore very high throughput.

A Social Enterprise which is applying for B Corporation status. The first fully automated sample-to-result platform. Launching in late 2023 with a respiratory assay to simultaneously detect flu A, flu B, RSV A, RSV B and Covid-19. Low cost testing with no CapEx as the platform is lent. Rugged and mobile it can be used where and when it is most need at infection hotspots.

We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 15 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyse and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analysing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by FIOS: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Twitter: @fiosgenomics Facebook: https://www.facebook.com/fiosgenomics/ Office Phone Number: +44 (0)131 322 3770 Office Address: Fios Genomics Ltd, BioCube 1, 13 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX

NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client's projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

genedrive plc is a molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use and robust point of need molecular platform for use in patient stratification (genotyping). We are passionate about the opportunity to build a sustainable business around molecular diagnostics and to play an important role in the diagnostic and treatment challenges presented by global health issues. The company launched the Genedrive MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, which was co-developed with the partners in the UK's National Health Service and is now used for routine clinical use.

We are a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine. Our ethos is to offer robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Our patented technologies allow for simultaneous detection of multiple targets in one reaction. If you have a project or collaboration in mind, we'd love to hear from you! Do you have a requirement for detecting multiple targets? Are you working with bacteria, viruses or fungus? We can help you achieve what you need with our dedicated team of experts. Drop us a line here or email us at info@genefirst.com

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient's genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients' health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.

DNA is the blueprint to what makes you who you are. It is the most valuable piece of personal information an individual will ever own. It is an appreciating asset that will continue to increase in value as genetic research continues to unlock mysteries in DNA over time. However, as soon as individuals send their saliva to a sequencing facility and their DNA is read, they relinquish all control over their data. Organisations that hold this data currently do not have the technology to safeguard it from data hacks/breaches and many legally share DNA data in plain text to third parties in multi-million dollar deals. This means that individuals not only are excluded from taking part in any value their DNA may hold but lose ownership and privacy of highly sensitive DNA data. We at Genomes.io believe individuals should be able to own, control access to and benefit from their most sensitive and valuable personal asset, their DNA. We are building a secure DNA sequencing, storage and sharing technology using state-of-the-art encryption and blockchain technologies to provide users with control over their whole genome sequence. This allows users to control access to segments of their genome in a repeat consent model to trusted professionals and accredited researchers in a secure, private and anonymous manner. Our platform acts as genomic data aggregator that provides research organisations with a more efficient genomic data acquisition model. However, we do so in a more equitable model in which individuals own, control and get paid for the data they wish to share. We aim to securely sequence and store 1 billion individual’s genomes in our DNA data bank and become the world’s largest, most secure and trusted genomic and health data marketplace to power the personalised medicine revolution. Genomes.io - Invest in Future You.

We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).

Genpax is revolutionising infectious disease investigation with IDEM, our groundbreaking surveillance tool using whole genome sequencing analysis. IDEM uses precision genomics to uncover the true relationship between bacterial isolates, offering a comprehensive solution to strain identification and outbreak management. IDEM not only provides unrivalled accuracy and resolution to transmission events, but also provides healthcare professionals with markers of clinical significance, signalling the need for swift containment or patient review.

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation. For 20 years, Gentronix Ltd has provided predictive toxicology solutions to global chemical industries; enabling our clients to optimise their development programmes via early identification of genotoxic hazard and assessment of chemical safety. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity products & services, along with assessment of skin sensitisation potential.

Genus is a world-leading animal genetics company. At the forefront of innovation in gene-editing, advanced reproductive biology, and other breakthrough breeding technologies, Genus R&D advances an agricultural practice thousands of years old – animal breeding. Our goal is to ensure the global food system continues to nurture healthy, productive animals that yield affordable, high-quality proteins for a sustainable future. We believe a more sustainable food system starts with better breeding and genetics. Through ABS Global (bovine) and PIC (porcine), we supply high-quality breeding animals with desirable characteristics to farmers, enabling them to produce better quality meat and milk more efficiently to feed the world more sustainably. Our breeding animals’ desirable characteristics include feed efficiency, disease resistance, growth rate, protein and fat content, and fertility. ABS Global is the world-leading provider of bovine genetics, reproduction services, technologies, and udder care products. Marketing in more than 70 countries around the globe, ABS has been at the forefront of animal genetics and technology since its founding in 1941. In bovine genetics, ABS serves more than 40,000 customers globally, including some of the world’s leading beef and dairy producers. PIC, which stands for ‘Pig Improvement Company,’ was founded in 1962 in Oxfordshire, England. PIC strives to make their customers the most successful pig producers in the world and their “Never Stop Improving” philosophy means a continuous effort to listen carefully to customers and drive innovation to create ever-increasing value for pig and pork producers.

In an increasingly fast-moving, complex, and uncertain world, it's never been harder for organizations and decision-makers to predict and navigate the future. Which is why GlobalData exists - its mission is to help clients decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Its solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

An introduction to GlycanAge® Our modern lifestyle has drastically changed the way we live and can impact our health for better or for worse. How can you gain a more complete picture of the current state of your health? Science has revealed a significant element that up until recently has largely been overlooked. Your biological age. While you have no control over the process of aging chronologically, your health and lifestyle can have a significant effect on your biological age. Your biological age is therefore not necessarily the same as your chronological age. Only about 54% of biological aging is determined by your genes, with about 46% being influenced by environmental factors. GlycanAge is a simple, ground-breaking test that analyses your glycobiology. Taking a GlycanAge® test is a vital step to improving your health. Your test results enable you to become aware of and monitor your biological age. This not only offers you an accurate insight into the current state of your health but can give you the powerful tool to make an informative decisions about lifestyle choices and changes.

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma's technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

At ichorbio, we are passionate about animals and believe there is a better way to do in vivo research. For us, the most important consideration was that our antibodies for in vivo use have the lowest possible impact on the animals they are being used in. This is how our mission was born: to create the best antibodies for in vivo research. To achieve our mission, we have created products that have lower endotoxin, higher purity and lower aggregation than other antibodies currently available on the market. Our antibodies adhere to all the same criteria as many of the larger manufacturers from a quality perspective with the added benefit that you can feel confident that you are doing the best for your animals. Best selling antibodies: RMP1-14: https://ichor.bio/ich1132-compared-to-be0146 RMP1-14 LALAPG: https://ichor.bio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg

IMU Biosciences is a UK-based techbio company that is revolutionizing immune powered precision medicine by mapping the immune system in unprecedented detail and scale. Their CytAtlas platform combines systems-level immunophenotyping with an AI platform to gain a new understanding of the immune system across health and disease.

Intract Pharma is a biotechnology company innovating in the field of oral delivery of complex proteins such as monoclonal antibodies with a special focus on treatment of gastrointestinal and systemic immune-mediated inflammatory diseases. Intract is applying it’s Phloral™ and Soteria™ technology platform for precision delivery of proteins to the colon for local tissue and systemic immunomodulation. Our vision is to transform care for millions of patients suffering from chronic diseases by converting their potent injectable biologic medicines into safe, effective and convenient take-at-home pills.

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we're working at the cutting edge in the new era of ‘digital biology'. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.

Advancing medicine and human health by transforming data into clinically meaningful insights. IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

Juno Bio is studying the vaginal microbiome and its impact on women’s health and fertility. Women can purchase sampling kits, take a sample at home, and send it to Juno Bio where theywill analyze the DNA and return the results.

Labocon is a renowned supplier of a wide range of Laboratory Equipment. The product range includes Analyzers, PCR products, General Laboratory Equipment like Mixers, Shakers, Temperature controlled Equipment, Balances & Microscopes etc. We provide as much information as possible about our products, and present them in simple and systematic way enabling the user to select the right product for their application conveniently. We make our client unperturbed by amending our products as per their needs. This is made achievable through our invincible staffs that constantly keep track of the research work going around the world. They are quite competent to add in the needs and refurbish the products. We are the one among the pinnacle to call upon for any requirement for your lab. Apart from this, our technical employees also work persistently on the automation of the products to help researchers in reaching their goal in a short time. We have laid our foundation over highest quality products with prompt & superior quality, after sales service and support.

Built by scientists, for scientists. Labstep is a digital research platform that allows researchers to collect, manage and share data securely in the cloud. With Labstep, lab management of reagents and equipment becomes easy and intuitive, allowing scientists to stay on top of their research. Our main objective is to allow scientists to spend more time researching and less time on data administration. Labstep is also tackling major issues faced by researchers around reproducibility of results. Over half of all scientific results published cannot be reproduced. To make data more reproducible, we allow real-time scientific data tracking for all researchers, thereby adding value to scientific output.

Leaf Expression Systems is a translational R&D and contract manufacturing business focused on the plant expression of proteins, vaccines, and complex natural products. They use the power of plant-based expression and plant biotechnology to enable their partners to innovate and impact, helping to drive their productivity and create.

LEX Diagnostics is a privately held molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable. Delivering a high-speed molecular test will redefine point-of-care diagnostics.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent. Such a solution has applications in a number of high-value sectors including health, food, defence and security. LDL has also established development partnerships with a number of end users including clinical microbiology, food producers and defence medicine.

Founded in 2001, Linguamaticsusesnatural language processing (NLP)-based text mining for high-value knowledge discovery and decision support.

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN." LivaNova has approximately 2,900 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Living DNA is a high definition DNA testing that challenges the concept of race and tackles ideas of separation through our 'One Family, One World'​ education programmes. With 75% of clients living overseas we do this globally. Presenting self-truth and letting science talk helps people change their lives. Putting ancestry into context allows people to celebrate not only how unique they are but also understand how we are all connected going back through history.

Funded and run by scientists, Ludger Limited is a life science company specialized in glycobiology. We have been serving and collaborating with world-leading life science organizations for 23 years. We pride ourselves on the high quality and consistency of our products which are recognized by regulators and used world-wide in the development and quality control of new biopharmaceuticals and biosimilars. Since our technology originated at the University of Oxford, it has evolved into our three core areas: 1) Products for Glycan Analysis 2) Analytical & Consulting Services 3) Research & Development

We are a team based in London, that develops a platform to help assess people with Parkinson's disease better. Motor assessment in Parkinson's disease is plagued by issues of subjectivity and reproducibility – not to mention systematic biases such as rater drift. To counter this, we are developing a platform, called Kelvin, that can be used from any device (e.g. smartphones or tablets). Named after the famous physicist so beloved of precise measurement, the platform allows researchers to record, score, store and analyse video of Parkinson's patients during motor assessment. Once captured and organised, the platform uses a cutting-edge computer vision technique, called pose estimation, to objectively track the movement of the patients down to the fingertip level and deliver objective metrics of core symptoms, such as tremor and bradykinesia.

An innovative C. elegans company, using our expertise and technology to provide quantified non-invasive assays of health outcomes for biotech, nutrition and other industries and research interests. - Prescreen compounds to reduce the number of experiments in mammals - Find effective and safe concentration ranges
 - Test mutants in signalling pathways - Screen libraries of mutants
 - Screen compound libraries 
 - Combine compounds and mutants
 - Adapt technology to address your questions We are a team of experts with a proven track record of: Designing customised C. elegans studies to provide answers to your specific ageing research questions Integrating C. elegans into drug discovery pipelines Working with innovative biotech and pharma companies Providing relevant, standardised, data rich assays

Magstim is a neurotechnology company that specializes in advanced brain stimulation and monitoring technologies. Founded in 1988 and headquartered in Whitland, Carmarthenshire, UK, Magstim is dedicated to advancing neurophysiology and neuromodulation. The company serves neuroscience researchers and clinicians globally, aiming to improve patient care for neurological and psychiatric disorders. Magstim develops and manufactures a range of precision neurotechnology tools. Their offerings include Transcranial Magnetic Stimulation (TMS) devices for non-invasive brain stimulation, high-density Electroencephalography (EEG) systems for monitoring brain activity, and transcranial Direct Current Stimulation (tDCS) devices for modulating neuronal activity. They also provide neurodiagnostic solutions, such as surgical nerve monitoring and intraoperative neurophysiology technologies. With a customer base that spans the globe, Magstim's products are utilized in research and treatment for conditions like depression, Parkinson’s disease, and epilepsy. Their tools have been referenced in over 20,000 clinical papers, highlighting their significant contribution to the field of brain science.

Malvern Panalytical is a global leader in the analytics of material and life sciences. We unleash the power of small things to make big things happen for our customers. Our vision is to make the world cleaner, healthier, and more productive. We partner with our customers to make their solutions possible through the power of precision measurements, our expertise, trusted data, and insights. Our people are partners in discovery. We collaborate with our customers and with each other to discover new possibilities and achieve breakthroughs. Our culture is a healthy, high-performance culture shaped by our values: Own it, Aim High and Be True. We’re committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. With over 2300 employees across the globe, we are part of Spectris plc, the world-leading precision measurement group. Malvern Panalytical. We’re BIG on small™

At Metofico, we specialise in developing no-code data analysis software tailored specifically for life science research. We are dedicated to making powerful tools accessible to all researchers—regardless of coding expertise. Our mission is to enhance the efficiency, reliability, and reproducibility of data analysis, empowering scientists to focus on advancing scientific discoveries instead of spending time on tedious data processing. Our suite of tools—ranging from Fiber photometry analysis to AI-driven rodent tracking and automated behaviour quantification—is designed to streamline preclinical research. Additionally, we provide custom software and hardware solutions tailored to the unique needs of each research project. We uphold the highest scientific standards and continuously refine our offerings based on valuable feedback from the research community.

Metrion Biosciences is a specialist preclinical drug discovery CRO - your trusted partner for ion channel screening, cardiac safety screening and neuroscience assays. We provide our customers with a range of in vitro screening services, including cardiac safety (GLP hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, we have 250 years experience managing ion channel research programmes.

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com. About the MEVION S250 Series: The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The Series is comprised of: • MEVION S250, offering highly stable, next-generation volumetric delivery capabilities • MEVION S250i with HYPERSCAN technology, overcoming pencil beam scanning uncertainties by delivering robust Intensity Modulated Proton Therapy treatment at hyper-speed • MEVION S250mx, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and guarantee 100 percent facility uptime

MiAlgae aims to revolutionize the current livestock and pet feed industries by producing microalgae rich in polyunsaturated fatty acids (PUFAs) to offer as a replacement to fishmeal in feed. 🚫🐟 Feed suppliers are in need of this alternative to fishmeal due to declining wild fish stocks and rising demand for Omega-3s. MiAlgae has developed an environmentally beneficial, effective, and simple solution of producing microalgae which delivers the required nutrients to livestock and pets without the need for fish. ♻️ Our zero-waste solution recycles the nutritional co-products from whisky production to grow Omega-3 rich microalgae, returning clean water in the process. 🌍 Our mission is to create a product that will contribute substantially towards the sustainable production of livestock, a prerequisite to fulfilling the needs of the growing world population. 💡Please check us out and follow us on: -https://www.twitter.com/mialgae -https://www.instagram.com/mialgae/

Microsaic Systems Plc is a Healthcare Technology company that provides online, at-line, and front-line workflows for therapeutics, diagnostics, manufacturing, & environmental epidemiology using analytical instruments and mass spectrometry.

EMD Millipore Corporation is a life sciences company that provides products and services for biotechnology, pharmaceuticals, and research and development.

Mootral is a British biotech company operating at the intersection of two existential crises of our time - climate change and antimicrobial resistance. Our natural solutions are enabling a shift to new standards in agriculture by allowing farmers and processors to significantly reduce their methane footprint and improve animal health, thereby future-proofing our global food ecosystem. mootral.com

🔵 What do we do? Multus is reinventing growth media for cell culture in cultivated meat and life science. From growth factors to serum-free supplements, we partner with companies looking for media breakthroughs to help accelerate their progress and de-risk their supply chain. 🔵 How do we do it better? We use a groundbreaking combination of data science, high-throughput automation and ISO-certified manufacturing to develop ingredients and formulations that reduce costs, eliminate animal-sourced components and enable scale-up. 🔵 Why do we do it? Our Mission is to make cultivated meat the sustainable and affordable choice, for everyone. To get there, every cultivated meat company needs to achieve the following growth media milestones: 1️⃣ Reduced input costs 2️⃣ Use of food-grade, animal-free ingredients that are sustainably sourced and aligned with regulation 3️⃣ Optimised formulations to improve bioprocess performance 4️⃣ Established scalable feedstocks where supply meets future production plans Companies that choose Multus see us as an indispensable partner in their journey to scaling cultivated meat production.

Myricx Bio is a biotech company headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs). They are focused on the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs.

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world's leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients' products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry's premier, trusted partner for successful development and commercialization outcomes. Learn more: https://namsa.com/about/client-testimonials/

NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

Nanothericsprovides products addressing the field of magnetic nanoparticle research and applications. In particular we aim to be the number one supplier of products for nanoparticle heating applications utilizing AC field and solenoid coil principles.

Nanovery is a biotechnology company founded in 2018 and based in Newcastle Helix, UK. The company specializes in nucleic acid nanorobotics, focusing on developing liquid nanorobot technology to advance nucleic acid research, particularly in RNA therapeutic analysis and biomarker quantification. Nanovery operates in the biotechnology sector, emphasizing research and development. The company's main offering is a proprietary platform that utilizes DNA nanorobotic sensors to quantify nucleic acid sequences in liquid samples. This platform simplifies the testing process by adding nanorobots to samples and measuring fluorescence to determine nucleic acid concentrations. Nanovery's technology supports RNA therapeutic development, biomarker analysis, and disease diagnostics, including early-stage detection. The integration of AI enhances data analysis and scalability, making the technology suitable for complex media. Nanovery has raised a total of $2.92 million in funding, with notable investors including Northstar Ventures and Innovate UK. The company aims to streamline testing protocols in biotech research, focusing on speed, cost-efficiency, and accuracy.

The National Health Service of the United Kingdom(NHS-UK)provides health care for all UK citizens based on their need for medical care rather than their ability to pay for it. The NHS was established in 1948 as one of the major social reforms following the Second World War and is funded by taxes.

NCIMB Ltd provides microbiology, analytical and biological material storage services. We work with companies from a diverse range of sectors including pharmaceutical. biotech, oil and gas, food and drink. Our microbiology services include GMP compliant identification of bacteria and fungi, whole genome sequencing and microbial community analysis, oilfield microbiology and qPCR. We are curators of the UK's National Collection of Industrial, Food and Marine Bacteria, and ship our strains around the globe.

Neurochase was founded by a team of physician-scientists led by Professor Steven Gill in response to the growing need for CED consultancy services in the life science industry. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol. He is a world leading expert in CED and has spent the past 20 years developing technology to facilitate highly accurate and safe targeting of deep brain structures using software and surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering chemotherapy directly to paediatric brainstem tumours using his novel implantable neurosurgical device. Our Science: Convection Enhanced Delivery (CED) provides a method of achieving effective doses of therapeutics homogenously in targeted brain volumes that cannot be achieved safely with systemic or CSF delivery. Therapies are infused into the brain via micro-catheters and can be distributed in tightly controlled doses throughout the required treatment volume. The blood brain barrier now acts to retain the therapy in the brain targets thereby minimising systemic and off-target exposure. We believe that safe and scalable delivery of novel therapeutics by CED is achievable and will transform human health by unlocking treatments to previously untreatable neurological disorders.

We’re here to accelerate your therapy’s journey through the complexities of drug discovery and development. Putting innovation at the forefront of our capabilities, industry-leading experts help you confidently and proactively answer critical questions around the safety and efficacy of your product with our gold-standard in vitro models. By harnessing the power of predictive data, we navigate this crucial step efficiently and cost-effectively to maximise the potential of your therapy achieving clinical and market success. By combining our unique expertise with cutting-edge technologies, we’ve created predictive in vitro models that offer targeted solutions to your complex problems. Our tissue model platforms, including retina, kidney and lung, reliably and accurately mimic in vivo physiology to take the guesswork out of drug development – providing answers to your questions and a window into the future of your therapy. Our intelligent preclinical models provide the reliable data you need to identify, avoid and mitigate risks and failures. By better understanding how your therapy will interact in vivo, you can make assured decisions to reduce drug attrition and give your safe and efficacious asset the best chance of reaching patients. In a nutshell, we help you save money, save time and save lives by getting ahead of the game.

For those creating a more sustainable future with biotechnology, we use AI and computational modelling to help precision fermentation alt protein companies optimise their downstream processing, so they can de-risk their ventures, speed up R&D and reduce costs.

Low-cost, rapid whole genome sequencing is the future of infection control and clinical microbiology. Next Gen Diagnostics offers the low cost, high throughput, and automated sequencing and bioinformatics for a range of application, including tracking the transmission of disease in hospitals and pathogen surveillance for public health labs.

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

ŌGI Bio offers our customers in the microbiology sector an affordable route into the automation of routine microbial culturing. We do so through a unique modular, retrofittable device that allows customers to choose the specific functions they require for their processes as and when they identify them. This gives our customers a flexible base from which to accelerate their innovation by increasing their R&D throughput.

Omecu are the developers of a high performance genomics analysis platform providing secure access to large scale distributed datasets. Our team have spent over 10 years researching and developing in this area - building software solutions that allow researchers to quickly analyse large genomic datasets whilst ensure the security of the underlying data for the data holder. The company was formed in early 2021 to build on the research and development work from the university in this area.

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, Germany and an office in Cambridge MA, USA.

🔒 Enabling a world of secure computing. Harnessing the power of light, we push the boundaries of what is possible in data security by bringing speed to always-encrypted data technology. Through optical computing, we accelerate Fully Homomorphic Encryption (FHE) beyond the capabilities of electrical computing, making secure data sharing and collaboration a reality for everyone, everywhere. To find out more, visit www.optalysys.com ✅ Join our unique community hub, the Innovation Lab, to develop your FHE skills with expert training, market insights, exclusive content and events. https://optalysys.com/register-for-innovation-lab/ 🔗 We are committed to building a home for exceptional talent. Keep an eye on our job vacancies https://optalysys.com/careers/ if you're interested in joining the team.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

When a five-year-old boy was blinded after a regular eye exam failed to spot a retinal detachment, his father made it his life's work to help eye care professionals by revolutionising retinal imaging. Optos was founded by Douglas Anderson with the goal to make a patient-friendly device to capture a digital ultra-widefield image of the retina. Today, millions of patients around the world have benefited from optomap® retinal imaging. You will find optomap systems in many independent High Street optometrists, as well as eye clinics at Great Ormond Street Hospital in London and Harvard Medical Center in Massachusetts. Our core products produce high resolution optomap images of 82% or 200◦ of the retina, something no other imaging device is capable of in a single comfortable capture. The most recent innovation from Optos integrates ultra-widefield retinal imaging and image-guided Optical Coherence Tomography (OCT). This combined device facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. More than 1,000 published and ongoing clinical trials as well as thousands of case studies and testimonials show the long-term value of optomap imaging and OCT in diagnosis, treatment planning, and patient engagement. As a division of Nikon Co. Ltd, Japan since 2015, Optos is approaching its 30th anniversary and proud to be recognized as a leading provider of devices to eye care professionals to provide a more complete approach to patient care.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

Orla Protein Technologies is a leader in Life Science, specializing in recombinant protein design, engineering, and manufacture for surface applications.

Osler is a UK-based diagnostics company whose purpose is to enable anyone, anywhere, to access, understand, and act on their health, to live healthier, happier, and longer lives. Osler has developed the Osler Origin – a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin will offer a wide portfolio of diagnostic tests and serve all major healthcare settings, globally. Osler was formed out of the University of Oxford in 2017, following decades of research from the same department that invented the portable electrochemical blood glucose sensor. The Company is headquartered in Oxford, UK.

Oxford BioDynamics (OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. OBD aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare with a portfolio of clinical tests and research tools based on its proprietary EpiSwitch® technology, uniquely capable of reproducibly translating 3D genome regulation for clinical application. The company's flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible. OBD's 24,000 sq ft headquarters in Oxford, UK, houses offices and state-of-the-art laboratory facilities. OBD's commercial team has an office in Gaithersburg, MD, USA, and the company has an ISO-certified laboratory in Penang, Malaysia. OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from 10,000+ samples in 30+ human diseases. OBD's proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone may respond to a disease or treatment. For more information, please visit oxfordbiodynamics.com.

As a leading global provider of diagnostic genomic solutions, our goal is to enable researchers and clinical decision makers to reach the right decisions for each patient, every time. The quality and innovation built into our products for NGS, arrays and FISH reflects our commitment to improving the future of genetic clinical care. We offer partnership and collaboration to our customers at every stage of their work.

Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world's first and only nanopore DNA and RNA sequencing platform. It's a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

Using advanced genetics and molecular biologyOxitechas developed a new and innovative solution to controlling the dangerous mosquito, Aedes aegypti.The Oxitec solution harnesses the natural instincts of male mosquitoes to find females in the wild. Oxitec has used genetic engineering to create ‘self-limiting’ male insects which seek out and mate with females. After an Oxitec male mosquito has successfully mated with a wild female, any offspring that result will not survive to adulthood, so the mosquito population declines.The Oxitec Control Programme is the system through which Oxitec mosquitoes are released and monitored over a predetermined and sustained period of time in an area with Aedes aegypti mosquitoes. By applying the Oxitec Control Programme to an area, the mosquito population in that area can be dramatically reduced or eliminated.Unlike conventional insecticides or pesticides, which kill insects indiscriminately, the Oxitec approach is targeted at a single species. This means that, as well as being more effective, it is much better for the environment than conventional tools.Oxitec is a subsidiary ofIntrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.

Our mission is to provide digital health technology to enhance clinical insights and endpoints. At P1vital, we bring clinical trials into the digital age, seamlessly integrating neuropsychology based technology in our eCOA platform. As well as traditional subjective assessments we have multiple validated objective measures that can be used to assess and track changes in behaviour and cognitive function. Our Facial Expression Recognition Task is recognized as a validated clinical assessment that has been implemented in more than 45 clinical trials worldwide. Our eCOA platform has proven success in managing the complex nature of CNS clinical trials across all phases of drug development and can be easily deployed in other therapeutic areas . If you are currently using different providers for each phase of your trial consider using P1vital as a one-stop solution. We would be delighted to show you how our eCOA platform can meet your needs across the whole clinical trial development process, saving you time, effort and reducing your costs. P1vital, the P1vital logo and all other P1vital product or service names are registered trade marks of P1vital Limited. © P1vital Limited and P1vital Products Limited. All rights reserved.

PartitionBio engages in technology platform that develops biomolecular tools for therapeutic and synthetic biology applications.

PAA design and build laboratory automation systems, used within the fields of life and physical sciences, which allow integration with many different types of laboratory instruments to perform even the most complex experiments, interacting with numerous data sources. These systems are suited to the pharmaceutical, biotechnology and academic sectors. We provide a design and installation service to ensure you get the integrated lab automation solution you require to satisfy all aspects of your business.

Perceptive Inc. is a global technology-enabled service provider dedicated to the biopharmaceutical industry. Recently rebranded as "Perceptive," the company focuses on advancing life-changing treatments through innovative services and solutions. Perceptive offers a range of services, including Perceptive Discovery, which aids in preclinical and first-in-human imaging to identify promising compounds. The Perceptive eClinical division enhances patient and clinical supply management, featuring services like Randomization & Trial Supply Management and Interactive Response Technology. Additionally, Perceptive Imaging provides expertise in scientific, regulatory, and operational aspects to support efficient data collection in clinical trials. With a client base that includes many leading pharmaceutical and biotech companies, Perceptive operates globally, ensuring smooth execution of clinical trials across various regions. The company has played a significant role in supporting nearly 12,000 clinical research trials and over 800 approvals, particularly in oncology and neuroscience, while upholding values of customer-centricity, quality, and accountability.

Services

Embrace the next era of drug discovery with PhaSER's revolutionary 8HUM Mouse Model. Unlock significant time, resource, and cost savings, propelling the swift delivery of innovative drugs to market. Join us in reshaping the landscape of pharmaceutical advancement. PhaSER is transforming the landscape of drug discovery through the introduction of the 8HUM Mouse Model, a groundbreaking advancement in creating a more human-like model for drug development. In response to the limitations posed by traditional animal models in studying drug efficacy, we have developed a mouse model that addresses these challenges and closely replicates human drug metabolism. Phaser has a team of experts involved in drug discovery, development, and clinical trials. • We can supply 8HUM mice or subcellular fractions, e.g. microsomes • We can supply detailed information on the characteristics of the 8HUM model. • We can discuss drug development projects and how 8HUM can contribute to a program of work at all levels.

Physiomics specialises in integrating Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics with disease biology expertise to help biotech and pharma companies streamline drug development. Our goal is to extract actionable insights from all relevant data to de-risk critical decisions across discovery, preclinical, and clinical stages. This includes the optimal design of preclinical and clinical studies to give your drug the best chance of success. We leverage cutting-edge computational tools, custom-built models, and our proprietary Virtual Tumour technology to provide tailored solutions that accelerate development and optimise outcomes for our clients. With a track record of supporting over 100 commercial projects and modelling more than 125 targets and drugs, Physiomics has become a trusted partner to industry leaders such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.

PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients.

PolyModels Hub kicked off in late 2022 with a mission: make modeling in Life Sciences easier for everyone and boost innovation. We started right here on Linkedin, building a community by sharing the latest research and open-source tools for life sciences. We are strong advocates for open-source modeling – it's akin to the transformation we saw in Software Dev and AI. That's why we recently introduced our open-source Hub, where you can sign up to discover, build and connect with the open-source community! Fast forward to 2024, and we decided to level up. We expanded PolyModels Hub to offer modeling services and products to the pharmaceutical industry. Our focus is on helping companies speed up their innovation in developing new drugs. We use the best digital design tools available, both open-source and proprietary, through our digital design approach and platform. The goal? Empower companies to launch medicines faster, save costs, and improve the quality of their products. And trust us, there's a lot more to come in our story!

Porvair Sciences, specialists in the manufacture of microplate products, serve Life Sciences, Biotechnology, R&D and Molecular Biology with microplate solutions for all applications, from sample preparation to high throughput screening via our global distributor network

Primerdesign is an innovative company focused on the design, manufacture, validation and supply of real-time PCR kits and reagents. Primerdesign is focused on developing improved solutions for real-time PCR. Founded in 2005 within Southampton University's School of Medicine, Primerdesign has unparalleled opportunities to access technology and clinically relevant material in pursuit of these goals. Primerdesign specialises in developing real-time PCR assays and reagents manufactured and validated to the very highest standard. Primerdesign developed the worlds first H1N1 swine flu detection kit in 2009 Primerdesign launched unique range of lyophilised ambient temperature stable qPCR reagents in 2012. Primerdesign was a central player in response to the horse meat contamination scandal in 2013. Primerdesign developed the Worlds first H7N9 bird flu detection kit for use in humans in response to the 2013 Chinese outbreak.

ProImmune's mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.

For when you need it all. We're here. We know scientists give it their all every day to reach their goals. Wherever your research takes you, Proteintech provides all of the antibodies you need to help you do that. All types and forms of antibodies are in stock for your experiment. We’ll be there for every step of your journey. With our GMP capabilities and recombinant custom antibody platform, we can provide the support to scale up from bench to clinic. Search the full catalog at ptglab.com.

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies. We have wide experience across the life sciences sector working with many different human and animal sample types including blood plasma, CSF, solid tissues, cell culture material etc. As a reflection of the quality of our approach, the purpose built, state-of-the-art research facility in Frankfurt is certified to ISO 9001:2015 and GCLP

We profile the fundamental building blocks of life, providing cross-sectional snapshots, like a CT scan for your blood. We want to impact both primary and secondary care pathways. Our mission is to light the way in which cancer is diagnosed, treated and monitored. We aspire to deploy at population-level within the UK and globally.

Prozomix Limited is an enzyme discovery and manufacturing company located in Haltwhistle, Northumberland, United Kingdom.

At Psyomics, we’re helping people get the mental health support they need, sooner. Led by CEO Dr Melinda Rees, Psyomics aims to revolutionise the way we assess, diagnose, triage, and treat mental health. Cambridge University Biotech spinout turned Healthtech, Psyomics was founded by Professor Sabine Bahn, Laboratory Director at the Cambridge Centre for Neuropsychiatric Research. Following more than six years of research and development, our product — CENSEO — is a digital platform that significantly reduces clinical triage and assessment time through dynamic patient-reported information capture. CENSEO was commercially launched in late 2022 for the assessment and triage of 15+ mental health conditions, used by more than 6,500 patients to date.

PulmoBioMed commercialises state-of-the-art exhaled breath condensate & aerosol sampling technology as part of a platform for disease and environmental diagnostics. Our lead product, PBM-HALE is a passive fluid aerosol sampler engineered to segregate exhaled and environmental particles by size. Our technology solves key pains in avoiding sample contamination, preventing sample loss and generating highly reproducible data with digital molecular precision. The first of a series of products, PBM-HALE has demonstrated utility in biological agent capture, genomic/microbiomic analytics, and metabolomic profiling, through a one-stop solution. Our vision is to develop the first hand-held biomolecular analyser for medical, veterinary, well-being and environmental use. Our mission is to deliver molecular diagnostic-grade health data from your lips to your hand. PulmoBioMed Ltd. is a Northumbria University spinout company supported by the Northern Accelerator, iCURe, and InnovateUK.

The Quadram Institute is a British center for research and training in food science and health.

Provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry.

Rayner manufactured the world's first IOL in 1949, and has remained at the forefront of innovation for over 70 years, focused on providing you and your patients with the best IOLs and ophthalmic solutions - always driven by science to improve patient outcomes and safety. Rayner is the only manufacturer of IOLs in the UK, with its state-of-the-art manufacturing plant and Global Headquarters on the South Coast of England. Rayner is a fast-paced and growing business with 500+ employees worldwide.

ReadyGo™ is a technology company dedicated to simplifying diagnostic testing by offering devices and assays that make testing more accessible and decentralised. These devices streamline sample collection and seamlessly integrate with existing tests on the market. ReadyGo also designs assays and diagnostic tests tailored for use on both our innovative diagnostic platforms and other laboratory-based systems. Our products are well-suited for human healthcare and can also be applied in agricultural and veterinary diagnostics and in forensic settings.

World-leading design and animation studio for Bio/Med/Tech. We help young as well as established companies convey the excitement and innovation of their research, technology and products to a wider audience - be it clients, investors or patients.

RevoluGen is a privately held scientific research and development company commercialising molecular tools with a specific focus on rapidly extracting long and pure DNA fragments from cells. RevoluGen's Nucleic Acid Isolation and Purification (NAIP) products have broad application across short- and long-read DNA sequencing, including in population genomics, epidemiological mutation screening and antibiotic microbial resistance gene monitoring. Fire Monkey significantly improves sequencing results by extracting long-fragment DNA with a simultaneous size selection function built into the protocol that minimises the small-fragment DNA contamination. Used independently, the size selection protocol of Fire Flower can improve the molecular ratio of any extraction kit and is compatible with all sequencing technologies. The Company headquarters, R&D, manufacturing and direct customer sales and support are based in the UK. RevoluGen serves customers worldwide and has secured agreements with world-leading molecular biology tools companies including Merck KGaA (sales), Cytiva (manufacturing), Tecan (automation) and A4P (logistics). Watch our film https://vimeo.com/465291714 and animation https://lnkd.in/dHy3E3s

Prevent target safety failures with unique data insights and cutting-edge approaches. ‍ Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities. Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.

All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.

A revenue generating producer of high value, natural biochemicals Creator of a flexible, scalable platform Innovator of versatile synthetic biology platforms Commercially selling ScotBio Blue, a natural blue extract from spirulina used as an internationally approved food colourant

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities. 14C Custom Radiolabelling for pre-clinical ADME studies 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate) GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance Stable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities Stable Labelling 13C 2H 15N GLP Analysis Certification and Problem Solving including GLP NMR www.selcia.com contact@selcia.com

Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST. This breakthrough technology is currently being applied to the world’s most prevalent diseases and infections where earlier and more prevalent diagnoses can make the biggest impact. Founded with the goal of developing PCR accurate point-of-care diagnostics for the world’s most deadly diseases, Senzo Health builds high sensitivity, low-cost, real-time testing technologies. PRICE Laboratory-based diagnostics are expensive, to the individual, the insurer, and the system. By lowering the price of modern diagnostics, we dramatically increase their use and value within healthcare. ACCURACY The Senzo Amplified Lateral Flow test is PCR-accurate. This means that for the first time we can bring testing for a range of new infections and diseases out of the laboratory and closer to the patient enabling a revolution in both diagnostics and treatments. SIMPLICITY Current diagnostics are too complex. From appointments to samples to laboratories to results. By simplifying diagnostics and bringing accurate and real-time testing to the patient, we can save money, save resources and save lives. SPEED Testing is about accurate results. The faster we can return a diagnosis, the sooner we can begin a treatment. Currently, patients and health care professionals often wait days for results. Real-time testing changes this forever, removing the gaps between consultation, testing, data and treatment. ACCESSIBILITY Accurate diagnostics today remain unevenly distributed. The only way to bring testing to patients in lower-income areas is to replace the complex central laboratory model with an affordable point-of-care diagnostics system without sacrificing accuracy.

Sequirus is one the largest cell-based influenza vaccine producer in the world. The company also makes antivenoms, and Q fever vaccine.

Sequential Skin is a Singapore-based healthcare organization that provides services such as genetics and microbiome research for the treatment of skin diseases.

Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world’s biomedical information to enable the most efficient analysis at scale.

Severn Biotech is a microbiology company that specializes in laboratory services and biotechnology.

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.

Singer Instruments make laboratory automation to accelerate research for biologists who want to make the world a better place. Singer Instruments was established in 1934 and has a long-standing track record developing and manufacturing mechatronic workstations and laboratory automation robotics. Our world-leading, specialist products are used to facilitate and accelerate genetic and genomic research around the world. We supply public and private research institutions in multiple facets of biological sciences including Genetics, Neuroscience, Systems Biology, Cancer Biology, Biofuel Engineering and microbiology. Our headquarters, on the edge of Exmoor National Park in Somerset, England, is a state-of-the-art factory with full, virtual prototyping facilities, precision CNC manufacture and robotic coordinate measurement for quality control. We design, manufacture, program, assemble and QC all of our core products on site. As an employee-owned company, Singer puts their people first. Singer Instruments are very proud to have won the Somerset Business Awards Employer of the Year; By supporting our teams and investing in our people, we get the best results for our customers. Having worked alongside and added value to laboratory research for over 40 years, we are a truly integrated and respected member of the genetics research community. Our tag line ‘a responsibility to science’, acts as a continual reminder for us to do our utmost to support, develop new technology, and add as much value as possible to the science and the scientific community we serve. Should you have any feedback, suggestions or collaborative opportunities that may help accelerate scientific research, we would be delighted to hear from you.

Sonrai is the only multi-omic cloud AI solution designed for precision medicine. Our experts have developed a Bioinformatics Cloud product explicitly designed to work with precision medicine data, alleviate pain points, and help succeed from early discovery through to clinical phases and beyond.

Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in Genomics and Histopathology, partnering with biotechnology, pharmaceutical, healthcare and academia. Source LDPath provides an end-to-end clinical diagnostic service, from histopathology, including digital pathology and AI, through to molecular diagnostic services. Source LDPath already supports over 85 NHS Trusts and a comprehensive network of Private Healthcare clinics to expand their diagnostic capabilities, ensuring diagnostic results are delivered within clinically actionable timeframes. Source LDPath brings pioneering expertise in digital pathology and AI implementation, helping NHS pathology departments digitise their workflows for streamlined operations and greater diagnostic reporting capacity, tailoring integration touchpoints to the specific requirements of the Hospital or Trust. • Cellular and digital pathology wet laboratory processing • Reporting - access a pool of over 200 specialist consultant pathologists • MDM and Second Opinions • Digital Implementation Support with AI integration • Connectivity and LIMS integration with Source HIVE™ Source Genomics provides a broad portfolio of multi-omic services, delivering high-quality data in Genomics, Spatial Transcriptomics, Proteomics and Epigenomics. Market-leaders in Sanger Sequencing and Next-Generation Sequencing Services, Source Genomics delivers bespoke laboratory expertise to excel your project at rapid turnaround times. • Sanger Sequencing • NGS - WGS, WES, RNA-seq • Oxford Nanopore Sequencing • Olink proteomics • Optical Genome Mapping • 10x Genomics Visium • Bioinformatics • And more Contact us today at enquiries@sourcebioscience.com.

SPT Labtech designs and makes products that transform the way scientists work. For over two decades, our expert scientists, engineers, and business innovators have created innovative solutions for liquid handling, sample preparation and management that help accelerate research and make a real difference to human health. We work collaboratively with our customers, building trusted relationships that enable us to deliver exceptional, personalized experiences designed for real world challenges in the lab. • Whether you operate on a nanolitre, microlitre or millilitre scale, our liquid handling solutions allow you to handle samples and reagents with accuracy and speed, across genomics, drug discovery and structural biology applications (firefly®, mosquito®, dragonfly®, apricot®) • Stay organized in the lab while saving valuable time and resources with our suite of automated sample management systems, including -80°C to ambient storage (comPOUND®, comPACT®, arktic®) and essential day-to-day tube management (BioMicroLab range, lab2lab) • Optimized cryo-EM sample and grid preparation is easy with chameleon® and Quantifoil, delivering consistently high-quality images and data.

Start Codon leverages the unique resources of the Cambridge Cluster to identify, seed-fund and drive the success of truly disruptive healthcare start-ups.

Stratech Scientific Ltd. is a UK-based distributor of life science research tools, established in 1983 by Sue Hallett. The company specializes in overcoming logistical challenges related to temperature-sensitive biological products. With a revenue of $8.5 million and a team of approximately 20 employees, Stratech has built a reputation for reliability and customer-centric services, offering a money-back guarantee on all products. Stratech distributes over 90,000 life science research tools globally, including antibodies, molecular biology tools, sample preparation reagents, and specialized biochemicals. The company serves a diverse customer base, including academic, pharmaceutical, and biotechnology research laboratories. It has longstanding relationships with institutions like the John Innes Centre and supports manufacturers in entering European markets. Stratech is known for its expertise in cold-chain distribution and provides technical support tailored to various research applications.

Strides Pharma Science is a global pharma company headquartered in Bengaluru and a footprint across 100 countries. We operate two business verticals, Regulated Markets and Emerging Markets. Our manufacturing footprint covers 8 manufacturing facilities in 4 continents, including 5 US FDA approved facilities and a dedicated R&D facility in India with global filing capabilities. Our core competence is in the development and manufacture of wide range of niche and technically complex pharmaceutical products. We are also among the world's largest soft gelatin capsule manufacturers. For more details, please visit www.strides.com

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, with over 1000 staff from 53 nationalities, including 900 scientists working on drug discovery programmes. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.

SynbiCITE is the UK's national centre for the commercialisation of synthetic biology. The prime objective of SynbiCITE is to accelerate and promote the commercial exploitation of synthetic biology research and technology. SynbiCITE's role as nucleating point for this rapidly emerging industry is designed in time to deliver sustained and substantial benefits to the UK economy. SynbiCITE is a unique collaboration of UK's leading academic institutions and industrial partners, ranging from start-ups to large multinational companies, and supporting organizations including the Northern Ireland, Scottish and Welsh Regional Governments and the Greater London Authority. SynbiCITE is one of seven IKCs set up to nucleate new industries, by closing the gap between scientific research and its commercial exploitation. IKCs are a key component of the UK's approach to the commercialisation of emerging technologies through creating early stage critical mass in an area of disruptive technology. SynbiCITE was set up in 2013 with a £28 million commitment over 5 years comprising of grants from Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Innovate UK and its industrial and academic partners. SynbiCITE and our partners, across the UK and globally, are committed to developing this technology through responsible innovation, which encompasses ethical, societal and environmental considerations.

Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 20- 25 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders. We take a long-term view, underpinned by a strategic capital base which enables us to maintain significant ownership positions in our companies and provides us with control and flexibility over the management of our portfolio. We believe we have the team, track record and skill-set to capture the superior returns available from commercialising exceptional science.

SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.

Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.

SyntheticGestalt is an AI startup focused on the life sciences sector, particularly in drug and enzyme discovery. Founded in 2018, the company operates from dual headquarters in London and Tokyo. It utilizes advanced machine learning models to enhance the design, discovery, and analysis of both small and large molecules. The company offers services in drug and enzyme discovery, collaborating with prestigious universities in the UK and Japan. This partnership emphasizes its commitment to scientific research and development in biotechnology. SyntheticGestalt has a diverse international team with expertise in entrepreneurship, pharmaceuticals, consulting, and AI, fostering a supportive work environment that encourages professional growth. With a small team of 11 to 50 employees, SyntheticGestalt is a private limited company incorporated in the UK. Its operations reflect a strong dedication to innovation in the life sciences, supported by grants and collaborations with academic institutions.

Tagomics is a privately held company founded in 2020, with 2-10 employees. It is working to transform disease diagnosis through genetic, epigenetic, and fragmentomic features to identify disease-associated biomarkers and provide insights for disease profiling.

Tata Elxsi is amongst the world's leading providers of design and technology services across industries, including Automotive, Broadcast, Communications, and Healthcare. Tata Elxsi is helping customers reimagine their products and services through design thinking and the application of digital technologies such as IoT (Internet of Things), Cloud, Mobility, Virtual Reality, and Artificial Intelligence. Tata Elxsi is truly home to a billion possibilities. We believe in opportunities for everyone - to be bold, and curious and seek to shape the future. Explore what's possible, discover what you love to do, and find accelerated paths for growth. At Tata Elxsi, you matter.

Founded in 1996 by a group of highly experienced healthcare professionals with a wide range of pharmaceutical industry and academic experience, The Micron Group has grown around this core of expertise, and now has offices in the UK, USA and South Africa. From these locations The Micron Group has global capabilities to deliver full clinical outsourcing , data management, medical communications and consultancy services. While initially an anti-infective specialized organisation, and still an authority in this field, The Micron Group has evolved to posses the expertise required to deliver our full range of services in the fields of respiratory, cardiovascular, neurology, dermatology, endocrinology, rheumatology, and oncology. Regardless of the field or the project, The Micron Group consistently strives to deliver a service that is flexible, preemptive and precise, ensuring projects are delivered on time and on budget, while going above and beyond expectation.

We make brand new ingredients on the which the world's biggest consumer product companies are building the healthier, more sustainable and more abundant products of the future. Making system-wide impact means starting from the beginning. We go all the way back to the farmyard, using agriculture's most abundant renewable resource: fiber-rich side streams that don't typically make their way into the food system, like stems, hulls, husks and cobs. We use deep science knowledge and analytics to identify unique opportunities. We then develop the science from manufacturing to application to create completely new and highly scalable solutions to global problems. With our first ingredient, Supplant™ sugars from fiber, your favorite treats can look, feel and taste like they're supposed to. But because it's made from fiber, sugars from fiber is lower in calories, has a low glycemic response compared to glucose, and is prebiotic.

STADA Thornton & Ross focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharmaceuticals. We’ve been caring for British customers and patients since 1922, and with state-of-the-art manufacturing sites in West Yorkshire and Lancashire, are determined to continue caring for people’s health for generations to come. We are one of UK's leading producers of consumer healthcare products, owning trusted brands such as Covonia, Savlon, Hedrin, Nizoral and Cetraben as well as the cleaning brand Zoflora, which is bought by more than two million households. In keeping with STADA’s global strategy, in the UK we also offer a broad portfolio of branded and generic medicines, across a wide range of therapeutic areas, including dermatology, respiratory, oncology, kidney disease, bone health and many more. With our proven generics and biosimilars, we support a sustainable and cost-efficient NHS, widening patient access to effective treatments. Are you looking for an exciting job opportunity to advance your career in the healthcare industry? Explore our job vacancies: www.thorntonross.com/careers

Torbay Pharma is a licence holder and global specialist in the manufacture and supply of terminally sterilized injectables for the hospital market. We work with generic pharmaceutical companies seeking to ensure their sterile injectable products get to market reliably and without delay. As a CMO and CDMO, we offer fill/finish services for terminally sterilised injectables into plastic and glass vials and ampoules. Our specialist portfolio includes licensed and unlicensed terminally sterilised injectables, electrolyte solutions for total parenteral nutrition (TPN) compounding and a range of non-sterile oral solutions. Established in the 1970s as part of the Torbay and Devon NHS Foundation Trust, we have grown into a 250-strong team operating from our purpose built manufacturing facility in Paignton, UK. November 2023 saw us receive investment from NorthEdge, we’re now Torbay Pharmaceuticals Ltd. Torbay Pharma offer niche product experience and capabilities, an agile approach and a team of experts who genuinely care. Our determination and flexibility at every step, ensure quality products are efficiently supplied to market, with clear communication and consultancy throughout the process. If you think we can help you with your next project, visit our website: www.torbaypharma.com

TrakCel design, deploy and support digital Cellular Orchestration Solutions that track and manage all the components of the Cell and Gene Therapy supply chain, helping therapy developers to deliver therapies to patients safely and efficiently for both clinical and commercial stage therapies. For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do. We innovate. We unite. We transform tomorrow. Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo. Join us. See the journey.

tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle. We build product strategies as well as design and execute development programmes and commercialisation activities. Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts, offer truly flexible bespoke solutions and support to maximise the value of products. We help to expedite the development and commercialisation of products for the benefit of patients worldwide.

Manufacturing.

Tropic Biosciences develops high-performing commercial varieties of tropical crops whichpromote grower well being, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. Some of the products being developed are disease resistant bananas and caffiene-free coffee.

Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). As the partner chosen by many leading industry and academic organisations for their drug discovery programmes, Ubiquigent's experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialisation.

Ultromics pioneers precision heart failure detection. Our groundbreaking platform, EchoGo®, is revolutionizing the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. Our technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. We target challenging cardiac diseases, starting with HFpEF, to support timely diagnosis and early intervention. In collaboration with the Mayo Clinic, Johnson & Johnson, and Pfizer, we are continuously developing innovative diagnostic tools aimed at halting the progression of heart failure. Learn more: https://www.ultromics.com/. Follow Ultromics on social media for the latest news, X: https://x.com/ultromics, LinkedIn: https://www.linkedin.com/company/ultromics/.

Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com

Virusight has developed an AI-powered digital Healthcare platform that enables affordable, ultra-fast diagnostic testing solutions that provide highly accurate results in less than 20 seconds. SpectraLIT®, Newsight Imaging's miniaturized Spectrophotometer device combined with Virusight's unique AI algorithm, is a revolutionary Digital Healthcare Platform for immediate medical diagnoses. (e.g, Pathogens, Urine Analysis, Early Cancer Biomarkers Detection and more) Virusight Diagnostic is a Joint Venture between Sheba‘s ARC, the medical innovation arm of Sheba Medical Center, Israel's largest hospital and Newsight Imaging, Manufacturer of SpectraLIT®.

We're creating a win-win situation for food producers, consumers and the environment, using innovative technology to transform whole plants, like carob & barley, into deliciously sustainable ingredients. Sourcing from abundance, we're making alternatives that leave a better taste in your mouth. No limits on flavour or innovation, just products that put people, planet and your palate first. Big Chocolate's number one on our list. With more than 1 million child labourers estimated to work in the Ivory Coast & Ghana alone, and more CO2 emissions pound-for-pound than cheese, lamb or chicken, the industry is ripe for change.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers. The company has raised significant investment to accelerate biotechnology innovations and has a team of 10 employees.

Yourgene Health (formerly Premaitha) develops molecular diagnostic products that will have a positive impact on human health and is currently focused in the field of prenatal screening.

Zetta provides large-scale genomic data management using distributed database technology and best practice security techniques to leverage genomicdata benefits while preserving data privacy.